Friday , September 17 2021

Great results achieved with serious illnesses with new therapy

A new version of therapy against eczema has been successfully tested

Atopic dermatitis is a chronic skin disease that has become more common in recent decades. Despite the fact that mild forms of the disease can often be considered relatively well with the external methods of treatment today, but for those who suffer from severe atopic dermatitis, there is little hope. This may change soon, thanks to the new form of therapy.

"The disease affects about 11 percent of all girls and boys in pre-school age and one to two percent of adults in Germany, and many diseases are chronic and severe," said the Hannover School of Medicine (MHH). The sufferers suffer from dry, scaly and reddened, itchy skin, and if the affected areas are clearly visible, add social stigma. Therefore, there is an urgent need for effective treatment options, but they were not yet available for severe forms of the disease. However, researchers from the Ministry of Health and the University of Veterinary Medicine Hanover (TiHo) have successfully tested a new approach. Their findings were published in the Journal of Allergy and Clinical Immunology.

The new active ingredient in the form of tablets can also help with severe forms of atopic dermatitis. (Image: SkyLine /

Heavy eczema is only partially curable

"Atopic dermatitis has a variety of causes, including irritants, allergens, microbial, hormonal and psychological effects," explains the experts. In the treatment of cortisone compounds and so-called calcineurin inhibitors, which are used externally, was central. According to experts, only immunosuppressive cyclosporine, which has many side effects, and dullymab antibodies are available for the treatment of particularly severe forms.

Dupilumab is a little complicated in use

Duplumab has been available for purposeful inhibition of allergy inflammation messengers for about a year and "represents a huge step forward in the treatment of critically ill patients," said Professor Dr. Honey. Thomas Werfel from the Clinic of Dermatology, Allergology and Venereology of the Ministry of Health. However, this will not help all patients well enough. In addition, the drug needs to be administered, which is especially difficult to tolerate in children who are particularly likely to suffer from eczema. The newly tested, however, is intended for oral administration.

New active ingredient for oral administration

The new active ingredient, which can be taken as a tablet, significantly improved the appearance of the skin in tests for 98 patients. "Already after eight weeks, the proportion of diseased skin, such as redness, blistering and scratches, has halved," MHH said. The drug is a "blocker of histamine-4 receptors." It interrupts the process of inflammation and relieves itching, preventing the effect of histamine on the cells.

Histamine-4 receptor with a key role

"The results of laboratory and in vivo mouse models that we have been constantly publishing since 2005 have shown that the histamine-4 receptor is an interesting target for the treatment of atopic dermatitis," explains the professor. Waiter Since then, researchers have intensively studied the use of inflammatory skin diseases. "We assume that the histamine-4 receptor blocker works regardless of the cause of atopic dermatitis and is currently investigating which patients may be most likely to benefit from new therapies," said Professor Werfel.

No side effects have been detected

According to scientists, in the current study, there were no side effects that were caused by the introduction of the drug, and now, with the participation of the team from Hanover, a large international study of about 400 patients will begin to find the optimal dosage of this drug. "We have been working on this topic for many years. The project is a very good example of translational research, that is, interdisciplinary medical research with the aim of promptly translating the results into clinical applications, "said Professor Dr. Honey. Manfred Kessan from the Institute of Pharmacology, Toxicology and Pharmacy Thio. (Pp)

Source link